Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Sionna Therapeutics, Inc. - Common Stock (NQ:SION)

36.06 UNCHANGED
Streaming Delayed Price Updated: 4:00 PM EST, Nov 3, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Sionna Therapeutics, Inc. - Common Stock

12 Health Care Stocks Moving In Tuesday's Pre-Market Session
 
Via Benzinga
12 Health Care Stocks Moving In Monday's After-Market Session
 
Via Benzinga
Sionna Therapeutics Announces Presentation of SION-719 and SION-451 Phase 1 Data and Poster of New Preclinical Data on the Impact of NBD1 Stabilizers on F508del-CFTR Half-Life at the 2025 North American Cystic Fibrosis Conference
From Sionna Therapeutics, Inc.
Via GlobeNewswire
Sionna Therapeutics Announces Initiation of PreciSION CF Phase 2a Trial Evaluating NBD1 Stabilizer, SION-719, When Added to Standard of Care in Participants with Cystic Fibrosis
From Sionna Therapeutics, Inc.
Via GlobeNewswire
Sionna Short Squeeze Fades As Raymond James Backs Cystic Fibrosis Breakthrough, RBC Warns Treatments Set High Bar
Via Stocktwits
Sionna Therapeutics to Present Data at the 2025 North American Cystic Fibrosis Conference
From Sionna Therapeutics, Inc.
Via GlobeNewswire
Sionna Therapeutics Appoints Caroline Stark Beer as Chief Business Officer
From Sionna Therapeutics, Inc.
Via GlobeNewswire
Sionna Therapeutics Reports Second Quarter 2025 Financial Results
From Sionna Therapeutics, Inc.
Via GlobeNewswire
Hut 8, Greenbrier And Other Big Stocks Moving Higher On Tuesday
 
Via Benzinga
Sionna Therapeutics Announces Presentation of Preclinical Data that Demonstrate Proprietary Dual Combination Therapies Enable Full CFTR Correction in CFHBE Model
From Sionna Therapeutics, Inc.
Via GlobeNewswire
Newly-Listed Sionna Therapeutics Touts Positive Data From Lung Disease Candidate In Healthy Volunteer Trial
Sionna's CF drug candidates SION-719 and SION-451 showed strong safety and PK results in Phase 1 trials, advancing to mid-stage studies in 2025. 
Via Benzinga
Sionna Therapeutics Announces Positive Phase 1 Data for NBD1 Stabilizers SION-719 and SION-451 and Advances Both Programs in Clinical Development for Cystic Fibrosis
From Sionna Therapeutics, Inc.
Via GlobeNewswire
Sionna Therapeutics to Present at the Goldman Sachs 46th Annual Global Healthcare Conference
From Sionna Therapeutics, Inc.
Via GlobeNewswire
Sionna Therapeutics to Present Preclinical Data During Oral Session at the 48th European Cystic Fibrosis Conference
From Sionna Therapeutics, Inc.
Via GlobeNewswire
Sionna Therapeutics Reports First Quarter 2025 Financial Results
From Sionna Therapeutics, Inc.
Via GlobeNewswire
Sionna Therapeutics to Present at The Citizens Life Sciences Conference 2025
From Sionna Therapeutics, Inc.
Via GlobeNewswire
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
 
Via Benzinga
Alcoa Posts Weak Revenue, Joins QXO And Other Big Stocks Moving Lower In Thursday's Pre-Market Session
 
Via Benzinga
Why Liberty Energy Shares Are Trading Higher By 9%; Here Are 20 Stocks Moving Premarket
 
Via Benzinga
Sionna Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results
From Sionna Therapeutics, Inc.
Via GlobeNewswire
AI Mobility Provider, Steel Veteran Made Trading Debuts
AI Mobility provider Webus International, steel industry veteran Luda Technology, Chinese ad services provider LZ Technology, and Singapore-based med-tech Basel Medical all made their public debuts... 
Via Talk Markets
Topics Artificial Intelligence Stocks / Equities
Sionna Therapeutics to Present at the 45th Annual TD Cowen Health Care Conference
From Sionna Therapeutics, Inc.
Via GlobeNewswire
Sionna Therapeutics Announces Closing of $219.2 million Upsized Initial Public Offering, Including Full Exercise of Underwriters’ Option to Purchase Additional Shares
From Sionna Therapeutics, Inc.
Via GlobeNewswire
Sionna Therapeutics, Titan America Made Public Debut
Cystic-fibrosis-focused Sionna Therapeutics made its public debut this week, with an upsized public offering. Meanwhile, Titan America had a modest opening, just slightly higher than its initial... 
Via Talk Markets
Topics Stocks / Equities
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.